{"name":"Kringle Pharma, Inc.","slug":"kringle-pharma-inc","ticker":"","exchange":"","domain":"","description":"","hq":"","founded":0,"employees":"","ceo":"","sector":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[{"name":"Neuroscience","slug":"neuroscience","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"oncology","drugs":[{"name":"KP-100IT","genericName":"KP-100IT","slug":"kp-100it","indication":"Relapsing forms of multiple sclerosis","status":"phase_3"}]},{"name":"Metabolic","slug":"metabolic","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"immunology","drugs":[{"name":"KP-100LI","genericName":"KP-100LI","slug":"kp-100li","indication":"Type 2 diabetes","status":"phase_3"}]}],"pipeline":[{"name":"KP-100IT","genericName":"KP-100IT","slug":"kp-100it","phase":"phase_3","mechanism":"KP-100IT is a small molecule that targets the S1P1 receptor.","indications":["Relapsing forms of multiple sclerosis"],"catalyst":""},{"name":"KP-100LI","genericName":"KP-100LI","slug":"kp-100li","phase":"phase_3","mechanism":"KP-100LI is a small molecule that targets the SGLT2 receptor.","indications":["Type 2 diabetes"],"catalyst":""}],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMinAFBVV95cUxNa3pKNWVVQWJKa01HNnNOTm5TVDBUWWNlV2dxNE1WYUhJb01CblEzZV8xWWtUb2VmajZrOGg0Zm40NGxqVmw5bm9RV28tV2cwQ05IelFxMGlyYTdzRXJRN1UwNmFzaGJNRVJubE9UQmRLTlBHR0FVZGRGRll5Sm9wcng1OGdvZFBxelhpTFZremVYX1hyQUtSUFIzOXk?oc=5","date":"2026-04-08","type":"pipeline","source":"openPR.com","summary":"Trends in Growth, Segment Analysis, and Competitive Strategies Influencing the Acute Kidney Injury Market - openPR.com","headline":"Trends in Growth, Segment Analysis, and Competitive Strategies Influencing the Acute Kidney Injury Market","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMikwFBVV95cUxPNWw2SC1fc2EzUnlmeGotaWJ2MkNfempIZllBc1l6RmUtMWFNZjdRS2praVFDZnFPSnhMS09OQ0JvNUtDVUNUZWs5MlFWUk1aeVRkZVY1ZG9wM1VsWEt6THpPMEFYdGdIakpzUjRxSlV5b3lsc3BTLU8xbHAwajNLOWRRRi1VWVlKelMyVWFMb205clU?oc=5","date":"2026-04-08","type":"pipeline","source":"openPR.com","summary":"Segmentation, Major Trends, and Competitive Overview of the Acute Spinal Cord Injury Market - openPR.com","headline":"Segmentation, Major Trends, and Competitive Overview of the Acute Spinal Cord Injury Market","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMipgFBVV95cUxOaGNjYlB0aU1OblVRTElMNUJyM2J6eDNDYkFfM3BGWXhHbVZCT2llTkk5RmowcFJucVJLb2EtR3U5RzJfRkRCZXBYNHhqR3VURmc3dG9WLTNGRHRKWHFIWWZ2ZFFHQUc4YzRLcGJjblF4N3BWaUQxYnBsYktfSVBzRFVOOU9mVWhjV3BVTnE1ZFdyV3pWQzY0Z3E4R0V4TjZPa2gwNXNR?oc=5","date":"2026-04-02","type":"pipeline","source":"Yahoo Finance","summary":"The Rise of 6 Emerging Therapies in a Critical Spinal Cord Injury Market Void | DelveInsight - Yahoo Finance","headline":"The Rise of 6 Emerging Therapies in a Critical Spinal Cord Injury Market Void | DelveInsight","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi0wJBVV95cUxPSkx5VHgxbGpTY0g1YXoyUDYwMDllbWxkd1pWZGZBYjJHbVhONUpXWHZMdDhrZ1RFRmxvZVAyVkRNUUUtZFFweGNUQXllby1IdnhkUkpZSUNRcmJIdlNaaEU1eGZHVFBjMmw2MlRlQ0t4NmpsWC1xQ18tUXNiU2RXMzN0amsyaG9UR1J1TnZJZTA3M3pjbjhuaG9KRVYwUWNyMlVnRjdRVFVwQkFUUUNNTEhhcE9VcXdvUHBud0plWERQZTAwOEJ4VjFEdFk4OEVud2tXY2tmRHA3TUJNVlc4cy1TXzVBQ3ZfbkpXc1FiTTlfME5SREJSemw0cGpwTExQTFhoWlFXYmpjcnRHOVk3ckR3czJvTEp5MU9aeFFkTk1ueE9vQ0k1NTd4MUJFNWRKVmdHM0tIek1PTk9mdV8xZ21ibDNHUTBYd0dpdGRTQUZvbUk?oc=5","date":"2026-03-30","type":"regulatory","source":"Barchart.com","summary":"Spinal Cord Injury Pipeline 2026: Latest FDA Approvals, Clinical Trials, and Emerging Therapies Assessment By DelveInsight | StemCyte, NervGen Pharma, VA Office of Research and Development, Kessler - ","headline":"Spinal Cord Injury Pipeline 2026: Latest FDA Approvals, Clinical Trials, and Emerging Therapies Assessment By DelveInsig","sentiment":"positive"},{"url":"https://news.google.com/rss/articles/CBMiX0FVX3lxTE5rT3JTOFFBa24wODN5TUpyTVltVzVwd0lTWUdGQW9GZlhqcy1SaV9jbkJIdkVWUmpWMjFjcVJJM3czSUo3N01JS0pOVHRBaUtLd2ViN2NVZzM4dGVRaUJV?oc=5","date":"2025-10-27","type":"pipeline","source":"nature.com","summary":"Cerebrospinal fluid extracellular vesicle-derived miR-9-3p in spinal cord injury with neuroprotective implications and biomarker development | Communications Biology - nature.com","headline":"Cerebrospinal fluid extracellular vesicle-derived miR-9-3p in spinal cord injury with neuroprotective implications and b","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiwgJBVV95cUxQZUVCMnFwcXoyWG40RV8yYnI1NkMtN3UyeUxoRGw4eW5Uckw5NnM1T2t1dkI5VVJPTFg4anhRQUQ4LXBoRnF4SDcxWHM5WjJMTFBwZ05FSVJMdzMtcm5fRlNJQ3Boc3RTVlc5YS04MUFWbnJNQkhZVXlseXZ0YzliRXFiMlc3Ym1EV2dDVDNhX0xtM2IwWXdqdnhidHdqVTNzY0RyTWVNblNpazJEOHl4X0c1T2Z1ZXhaSGJoLXo4ZlZaOVYwOXBRSm80NFkzWThpZWktVXpRanhvYUt5MkE5YXNLNktvbE1zYmt2MUozRDR5Q3k1SFh6M3JMaUc4em41aW1XSWsxcF8xTmhxMGtsRzhJRWUzU0MzUkdZRS1mUjBCNHUzaTIwRV93QWpmOXIxdzVtbE8xOXh2YjB2c3E5bjhn?oc=5","date":"2025-02-19","type":"pipeline","source":"PR Newswire","summary":"Spinal Cord Injury Drug Treatment Market is Predicted to Reach New Heights with the Anticipated Launch of Emerging Therapies and Breakthroughs by 2034 | DelveInsight - PR Newswire","headline":"Spinal Cord Injury Drug Treatment Market is Predicted to Reach New Heights with the Anticipated Launch of Emerging Thera","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMihgFBVV95cUxQMmIzcU9WUTVqR1VLRTZPSUlNRTdraTl2RDVJZ3BKbDdtNGs0YWlfRXZ4a2lGd0RjSFczWEdUQUg4MHRjTXpLWW5XRWxFTDRHdUdjQXNQTnl6cDloQ1F5OEpuNl82blAyX2ZXNTh6SC0xc09sTlF4czVaTmxIazBCaVRlRzdaZw?oc=5","date":"2024-03-19","type":"pipeline","source":"Bioprocess Online","summary":"Eying Up The ERA Of Topical Biologics - Bioprocess Online","headline":"Eying Up The ERA Of Topical Biologics","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiqAJBVV95cUxNNnBZOW9Vbm15ckZMOEpYSkN1aHNBdWdDeFF3OExXUWNEQjNUMmg4bmh0cm9MTDhMMG1BMnFLM0t5Z3daaGJDbTcxcHlsQVE2WTVHZVVLczlpeUgzUWQxb240YVdYOGg4WGFNc01tU0NUaHNCY3ljTWpjWHNFb19uSHE0MEE3LXo0eW9vQ2xSR1FuLV84cFZnUDhVWjR6WkgtWHdkWFE2aV9NOWZvQnQ0TzFWWUxSREpwU1hMVXNwR005SnFsWVVzT2FvNFhsT1RpOHVKejJIWU9ZNmpBbXBDSXNvZHd5M3JaUFJEbkJMN0NRVDNwUGIxUmVvcEpJWkxRQk10OEJ3NmtJVXlFY2VURW1XUVdfTUo3YjB1MkRQd19UWXY0QmY4OQ?oc=5","date":"2024-01-04","type":"pipeline","source":"GlobeNewswire","summary":"Claris Bio Emerges From Stealth With a New Investor and - GlobeNewswire","headline":"Claris Bio Emerges From Stealth With a New Investor and","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiggFBVV95cUxPalFZbHRFVllMLUtMb09pb1VvYWtnWTNNLVRCQmFWWTFXZ2d6b0V3cjhhdnFRYVBVd25zclRSYUFJendSVkZmNXU1TEdKeTVuWmVTZzBadzVId25NODU3QzAxVGs0RnR4RVFrc2ZId3pObksxSVVCZGc1bFp4UF80NTd3?oc=5","date":"2019-08-18","type":"pipeline","source":"Market.us","summary":"Amyotrophic Lateral Sclerosis (ALS) Treatment Market - Market.us","headline":"Amyotrophic Lateral Sclerosis (ALS) Treatment Market","sentiment":"neutral"}],"patents":[],"drugCount":2,"phaseCounts":{"phase_3":2},"enrichmentLevel":2,"visitCount":2,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}